WeVote
Log In

Bill

Bill

HF 4349

Provisions governing hospital reimbursement for biological products to treat rare diseases modified.

2025-2026 Regular Session Introduced by Kristin Bahner and 4 co-sponsors

Minnesota bill HF 4349 modifies hospital reimbursement rates for biological products treating rare diseases, affecting patient access and healthcare costs.

Introduction and first reading, referred to Health Finance and Policy
#healthandhealthdepartment #hospitalsandhealthfacilities
0
WeVote Research Nonpartisan
Bill Summary · HF 4349

Legislative bill overview

HF 4349 modifies how hospitals in Minnesota are reimbursed for biological products used to treat rare diseases. The bill adjusts reimbursement provisions, likely addressing payment rates, coverage policies, or administrative requirements for these specialized treatments. The specific modifications have been referred to the Health Finance and Policy committee for review.

Why is this important

Rare disease treatments—particularly biologics—are among the most expensive medications in healthcare. How hospitals are reimbursed for these drugs directly affects patient access, hospital financial sustainability, and overall healthcare costs. Changes to reimbursement policy can either expand or restrict treatment availability depending on the direction of the modifications.

Potential points of contention

  • Cost implications: Whether modified reimbursement rates adequately cover hospital expenses without shifting costs to patients or insurance premiums
  • Patient access: Risk that reduced reimbursement could limit hospital willingness to stock or administer expensive biologics for rare disease patients
  • Payer burden: Insurance companies and public programs may face increased costs if reimbursement rates are raised, affecting overall healthcare spending and premium levels

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.